Author's response to reviews

Title: Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report

Authors:

Brett Hughes (brett_hughes@health.qld.gov.au)
Desmond Yip (dyip@med.usyd.edu.au)
David Goldstein (GoldsteinD@SEAHS.NSW.GOV.AU)
Paul Waring (paul.waring@petermac.org)
Victoria Beshay (Victoria.beshay@petermac.org)
Guan Chong (guan.chong@act.gov.au)

Version: 2 Date: 16 September 2004

Author's response to reviews: see over
Dear Sir/Madam

Re: Manuscript 3780991024070032 for BMC Cancer
Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report

We would like to thank the reviewer for his helpful and constructive comments. We have made the following changes to the manuscript.

1. The apostrophes have been removed from GISTs.
2. We would like to clarify that radiation therapy was offered to the patient but he declined and this is now documented in the case report.
3. We have stated that exon 9 mutations have a much worse prognosis than exon 11 with reference to the Heinrich paper (reference 8). We state the difference is likely to be due to differences in downstream signalling affecting the susceptibility of the GIST to imatinib and in our case may have compounded the problem with reduced CSF levels of the drug. The presence of the exon 9 mutation in the tumour is now stated in the abstract.
4. The patient has passed away since submission of our original manuscript and we have recorded this in the history.

We hope these changes will be acceptable to you.

Your faithfully,

Dr
Staff Specialist in Medical Oncology
Senior Lecturer, Canberra Clinical School, University of Sydney
Senior Lecturer, ANU Medical School, Australian National University